Nanoscope Therapeutics announced that Dr. Christine Kay, Director of Clinical Research and Retinal Genetics, Vitreoretinal Associates in Gainesville,will present 4-year data from Nanoscope's MCO-010 retinitis pigmentosa program at the 59th Annual Scientific Meeting of the Retina Society, taking place September 23-26, 2026, in Los Angeles, California.

Presentation Details:

Presentation Title: Lasting Vision Improvement With MCO-010 Optogenetic Therapy: REMAIN 4-Year Study Data From the RESTORE Phase 2b/3 Trial for Retinitis Pigmentosa

Presenter: Christine Kay, MD

Date & Time: Wednesday, September 23, 2026, 3:15 PM PT

Location: Fairmont Century Plaza Hotel, Los Angeles, California

Dr. Kay will present expanded long-term durability of patient benefit in patients treated with MCO-010 (sonpiretigene isteparvovec, Mogenry). These data demonstrate that MOGENRY®-dosed patients continue to maintain visual acuity gains long after treatment. Mogenry is the only program to demonstrate sustained restoration of visual acuity with long-term durability, and the BLA for Mogenry has been accepted and filed by the FDA.